Masanori Kuroha

Chuo, 1038426, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Usefulness of Mirogabalin in Central Neuropathic Pain After Stroke: Post Hoc Analysis of a Phase 3 Study by Stroke Type and Location.

Usefulness of Mirogabalin in Central Neuropathic Pain After Stroke: Post Hoc Analysis of a Phase 3 Study by Stroke Type and Location.

Journal: Pain and therapy

Published: March 19, 2024

Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia.

Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia.

Journal: Pain and therapy

Published: December 21, 2022

Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia.

Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia.

Journal: Neurology

Published: April 04, 2022

A review of a new voltage-gated Ca2+ channel α2δ ligand, mirogabalin, for the treatment of peripheral neuropathic pain.

A review of a new voltage-gated Ca2+ channel α2δ ligand, mirogabalin, for the treatment of peripheral neuropathic pain.

Journal: Expert opinion on pharmacotherapy

Published: August 25, 2021

Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies.

Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies.

Journal: Clinical therapeutics

Published: February 03, 2021

Pharmacological, pharmacodynamics, and clinical profile of mirogabalin besylate (Tarlige® tablets 2.5 mg∙5 mg∙10 mg∙15 mg)

Pharmacological, pharmacodynamics, and clinical profile of mirogabalin besylate (Tarlige® tablets 2.5 mg∙5 mg∙10 mg∙15 mg)

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica

Published: December 03, 2019

Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study.

Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study.

Journal: Pain and therapy

Published: November 19, 2019

Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain.

Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain.

Journal: Journal of diabetes investigation

Published: March 20, 2019

Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients.

Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients.

Journal: Journal of diabetes investigation

Published: November 20, 2018

Discovery of DS-6930, a potent selective PPARγ modulator. Part I: Lead identification.

Discovery of DS-6930, a potent selective PPARγ modulator. Part I: Lead identification.

Journal: Bioorganic & medicinal chemistry

Published: July 20, 2018

Discovery of DS-6930, a potent selective PPARγ modulator. Part II: Lead optimization.

Discovery of DS-6930, a potent selective PPARγ modulator. Part II: Lead optimization.

Journal: Bioorganic & medicinal chemistry

Published: July 20, 2018

Synthesis and biological evaluation of novel (-)-Cercosporamide derivatives as potent selective PPARγ modulators.

Synthesis and biological evaluation of novel (-)-Cercosporamide derivatives as potent selective PPARγ modulators.

Journal: European journal of medicinal chemistry

Published: April 09, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026